Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype. One of the earliest reports on the pharmacology of DMPP describing it as a ganglion-stimulating hypertensive agent came from Graham Chen and his co-workers at Parke Davis & Co.
This page contains content from the copyrighted Wikipedia article "Dimethylphenylpiperazinium"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
